CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response
Furthermore, it has also recently been hypothesized that DNA methylation may alter an individual’s responsiveness to psychiatric drugs, possibly due to variations in serotonin synthesis genes(7). [...]investigation into the effects of differential methylation on the efficacy of treatments in other c...
Gespeichert in:
| Veröffentlicht in: | Epigenomics 2017-05, Vol.9 (5), p.595-597 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 597 |
|---|---|
| container_issue | 5 |
| container_start_page | 595 |
| container_title | Epigenomics |
| container_volume | 9 |
| creator | Horsburgh, Steven Ciechomska, Marzena O'Reilly, Steven |
| description | Furthermore, it has also recently been hypothesized that DNA methylation may alter an individual’s responsiveness to psychiatric drugs, possibly due to variations in serotonin synthesis genes(7). [...]investigation into the effects of differential methylation on the efficacy of treatments in other common diseases appears worthwhile. Potential systemic sclerosis biomarkers and treatment Given these data and the relatively well-established role of differentially methylated drug metabolism enzyme genes in modification of the responsiveness to drug treatment, it is plausible that DNA methylation may also serve as a biomarker of treatment response in other rheumatic conditions associated with aberrant epigenetic profiles such as systemic sclerosis (SSc)(12 ,13). Future perspective Studies which highlight epigenetic modifications associated with response to treatment not only possess enormous clinical utility in terms of optimizing patient care, but may also aid in reducing the economic burden associated with unnecessary drug prescriptions. [...]once studies such as this are validated in larger cohorts, it is essential that standardized procedures for measuring markers across different genomic sites are implemented. |
| doi_str_mv | 10.2217/epi-2017-0011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1892724063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1892724063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-54a0d5bffc3aca442f24b4a4f7a52947c1ab04897f5b6b7640de5a33baf62bbb3</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMoKurRqxS8eKkmadq0R1n8AsGLggchTNKJG902NUkP_nuzrHoQDAOZgWdekoeQY0bPOWfyAidXcspkSSljW2SfyZqWrOPP2789Y3vkKMY3mk_F265hu2SPt0LItpb75GUx3ZRxQuOsM8WAafm5guT8WEAqwhLnAZJ3fQEhLYNLLha9g9fRx9xBrmKA8I6h8LZIASENOOY9jJMfIx6SHQuriEff9wF5ur56XNyW9w83d4vL-9IIRlNZC6B9ra01FRgQglsutABhJdS8E9Iw0FS0nbS1brRsBO2xhqrSYBuuta4OyNkmdwr-Y8aY1OCiwdUKRvRzVKztuOSCNlVGT_-gb34OY36d4rxjDesq0Waq3FAm-BgDWjUFl3_6qRhVa_Mqm1dr82ptPvMn36mzHrD_pX88Z6DbAHZOc9ZjHI4G1WbKG864Ef8J_wKYSpL4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2291619348</pqid></control><display><type>article</type><title>CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response</title><source>ProQuest Central (Alumni Edition)</source><source>ProQuest Central UK/Ireland</source><source>PubMed Central</source><creator>Horsburgh, Steven ; Ciechomska, Marzena ; O'Reilly, Steven</creator><creatorcontrib>Horsburgh, Steven ; Ciechomska, Marzena ; O'Reilly, Steven</creatorcontrib><description>Furthermore, it has also recently been hypothesized that DNA methylation may alter an individual’s responsiveness to psychiatric drugs, possibly due to variations in serotonin synthesis genes(7). [...]investigation into the effects of differential methylation on the efficacy of treatments in other common diseases appears worthwhile. Potential systemic sclerosis biomarkers and treatment Given these data and the relatively well-established role of differentially methylated drug metabolism enzyme genes in modification of the responsiveness to drug treatment, it is plausible that DNA methylation may also serve as a biomarker of treatment response in other rheumatic conditions associated with aberrant epigenetic profiles such as systemic sclerosis (SSc)(12 ,13). Future perspective Studies which highlight epigenetic modifications associated with response to treatment not only possess enormous clinical utility in terms of optimizing patient care, but may also aid in reducing the economic burden associated with unnecessary drug prescriptions. [...]once studies such as this are validated in larger cohorts, it is essential that standardized procedures for measuring markers across different genomic sites are implemented.</description><identifier>ISSN: 1750-1911</identifier><identifier>EISSN: 1750-192X</identifier><identifier>DOI: 10.2217/epi-2017-0011</identifier><identifier>PMID: 28447857</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Arthritis ; Biomarkers ; Cancer therapies ; CpG islands ; Deoxyribonucleic acid ; Disease ; DMARDs ; DNA ; DNA methylation ; Drug metabolism ; Drugs ; Epigenetics ; Fibroblasts ; Gene expression ; Genes ; Genomes ; Kinases ; MicroRNAs ; Musculoskeletal system ; Pathogenesis ; Patients ; Rheumatoid arthritis ; Serotonin ; Substance abuse treatment ; Systemic sclerosis ; T lymphocytes</subject><ispartof>Epigenomics, 2017-05, Vol.9 (5), p.595-597</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd May 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-54a0d5bffc3aca442f24b4a4f7a52947c1ab04897f5b6b7640de5a33baf62bbb3</citedby><cites>FETCH-LOGICAL-c410t-54a0d5bffc3aca442f24b4a4f7a52947c1ab04897f5b6b7640de5a33baf62bbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2291619348/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2291619348?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,21389,27924,27925,33530,33531,43659,64385,64387,64389,72469,74104</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28447857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Horsburgh, Steven</creatorcontrib><creatorcontrib>Ciechomska, Marzena</creatorcontrib><creatorcontrib>O'Reilly, Steven</creatorcontrib><title>CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response</title><title>Epigenomics</title><addtitle>Epigenomics</addtitle><description>Furthermore, it has also recently been hypothesized that DNA methylation may alter an individual’s responsiveness to psychiatric drugs, possibly due to variations in serotonin synthesis genes(7). [...]investigation into the effects of differential methylation on the efficacy of treatments in other common diseases appears worthwhile. Potential systemic sclerosis biomarkers and treatment Given these data and the relatively well-established role of differentially methylated drug metabolism enzyme genes in modification of the responsiveness to drug treatment, it is plausible that DNA methylation may also serve as a biomarker of treatment response in other rheumatic conditions associated with aberrant epigenetic profiles such as systemic sclerosis (SSc)(12 ,13). Future perspective Studies which highlight epigenetic modifications associated with response to treatment not only possess enormous clinical utility in terms of optimizing patient care, but may also aid in reducing the economic burden associated with unnecessary drug prescriptions. [...]once studies such as this are validated in larger cohorts, it is essential that standardized procedures for measuring markers across different genomic sites are implemented.</description><subject>Arthritis</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>CpG islands</subject><subject>Deoxyribonucleic acid</subject><subject>Disease</subject><subject>DMARDs</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>Drug metabolism</subject><subject>Drugs</subject><subject>Epigenetics</subject><subject>Fibroblasts</subject><subject>Gene expression</subject><subject>Genes</subject><subject>Genomes</subject><subject>Kinases</subject><subject>MicroRNAs</subject><subject>Musculoskeletal system</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Rheumatoid arthritis</subject><subject>Serotonin</subject><subject>Substance abuse treatment</subject><subject>Systemic sclerosis</subject><subject>T lymphocytes</subject><issn>1750-1911</issn><issn>1750-192X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kE1LxDAQhoMoKurRqxS8eKkmadq0R1n8AsGLggchTNKJG902NUkP_nuzrHoQDAOZgWdekoeQY0bPOWfyAidXcspkSSljW2SfyZqWrOPP2789Y3vkKMY3mk_F265hu2SPt0LItpb75GUx3ZRxQuOsM8WAafm5guT8WEAqwhLnAZJ3fQEhLYNLLha9g9fRx9xBrmKA8I6h8LZIASENOOY9jJMfIx6SHQuriEff9wF5ur56XNyW9w83d4vL-9IIRlNZC6B9ra01FRgQglsutABhJdS8E9Iw0FS0nbS1brRsBO2xhqrSYBuuta4OyNkmdwr-Y8aY1OCiwdUKRvRzVKztuOSCNlVGT_-gb34OY36d4rxjDesq0Waq3FAm-BgDWjUFl3_6qRhVa_Mqm1dr82ptPvMn36mzHrD_pX88Z6DbAHZOc9ZjHI4G1WbKG864Ef8J_wKYSpL4</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Horsburgh, Steven</creator><creator>Ciechomska, Marzena</creator><creator>O'Reilly, Steven</creator><general>Future Medicine Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response</title><author>Horsburgh, Steven ; Ciechomska, Marzena ; O'Reilly, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-54a0d5bffc3aca442f24b4a4f7a52947c1ab04897f5b6b7640de5a33baf62bbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Arthritis</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>CpG islands</topic><topic>Deoxyribonucleic acid</topic><topic>Disease</topic><topic>DMARDs</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>Drug metabolism</topic><topic>Drugs</topic><topic>Epigenetics</topic><topic>Fibroblasts</topic><topic>Gene expression</topic><topic>Genes</topic><topic>Genomes</topic><topic>Kinases</topic><topic>MicroRNAs</topic><topic>Musculoskeletal system</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Rheumatoid arthritis</topic><topic>Serotonin</topic><topic>Substance abuse treatment</topic><topic>Systemic sclerosis</topic><topic>T lymphocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Horsburgh, Steven</creatorcontrib><creatorcontrib>Ciechomska, Marzena</creatorcontrib><creatorcontrib>O'Reilly, Steven</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Epigenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horsburgh, Steven</au><au>Ciechomska, Marzena</au><au>O'Reilly, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response</atitle><jtitle>Epigenomics</jtitle><addtitle>Epigenomics</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>9</volume><issue>5</issue><spage>595</spage><epage>597</epage><pages>595-597</pages><issn>1750-1911</issn><eissn>1750-192X</eissn><abstract>Furthermore, it has also recently been hypothesized that DNA methylation may alter an individual’s responsiveness to psychiatric drugs, possibly due to variations in serotonin synthesis genes(7). [...]investigation into the effects of differential methylation on the efficacy of treatments in other common diseases appears worthwhile. Potential systemic sclerosis biomarkers and treatment Given these data and the relatively well-established role of differentially methylated drug metabolism enzyme genes in modification of the responsiveness to drug treatment, it is plausible that DNA methylation may also serve as a biomarker of treatment response in other rheumatic conditions associated with aberrant epigenetic profiles such as systemic sclerosis (SSc)(12 ,13). Future perspective Studies which highlight epigenetic modifications associated with response to treatment not only possess enormous clinical utility in terms of optimizing patient care, but may also aid in reducing the economic burden associated with unnecessary drug prescriptions. [...]once studies such as this are validated in larger cohorts, it is essential that standardized procedures for measuring markers across different genomic sites are implemented.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>28447857</pmid><doi>10.2217/epi-2017-0011</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-1911 |
| ispartof | Epigenomics, 2017-05, Vol.9 (5), p.595-597 |
| issn | 1750-1911 1750-192X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1892724063 |
| source | ProQuest Central (Alumni Edition); ProQuest Central UK/Ireland; PubMed Central |
| subjects | Arthritis Biomarkers Cancer therapies CpG islands Deoxyribonucleic acid Disease DMARDs DNA DNA methylation Drug metabolism Drugs Epigenetics Fibroblasts Gene expression Genes Genomes Kinases MicroRNAs Musculoskeletal system Pathogenesis Patients Rheumatoid arthritis Serotonin Substance abuse treatment Systemic sclerosis T lymphocytes |
| title | CpG-specific methylation at rheumatoid arthritis diagnosis as a marker of treatment response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T03%3A39%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CpG-specific%20methylation%20at%20rheumatoid%20arthritis%20diagnosis%20as%20a%20marker%20of%20treatment%20response&rft.jtitle=Epigenomics&rft.au=Horsburgh,%20Steven&rft.date=2017-05-01&rft.volume=9&rft.issue=5&rft.spage=595&rft.epage=597&rft.pages=595-597&rft.issn=1750-1911&rft.eissn=1750-192X&rft_id=info:doi/10.2217/epi-2017-0011&rft_dat=%3Cproquest_cross%3E1892724063%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2291619348&rft_id=info:pmid/28447857&rfr_iscdi=true |